Related Experiment Video

Updated: Mar 20, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma

Thomas E Hutson1, Gregory R Thoreson1, Robert A Figlin1

  • 1From the Texas A&M Health Science Center, Bryan TX; Baylor-Sammons Cancer Center, Dallas, TX; US Oncology, Texas Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 2, 2016
PubMed

Insights

Recent advances in immune checkpoint inhibitors offer new hope for advanced renal cell carcinoma (RCC) patients. Optimal treatment sequencing and novel therapies are under investigation, focusing on patient outcomes and quality of life.

Area of Science:

  • Oncology
  • Immunotherapy
  • Genitourinary Cancers

Background:

  • The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving.
  • Immune checkpoint inhibitors (ICIs) have emerged as a significant breakthrough, particularly for treatment-refractory disease.
  • Significant challenges remain in managing advanced RCC, including cost, toxicity, and defining appropriate clinical endpoints.

Purpose of the Study:

  • To review the current dynamic treatment paradigm for advanced renal cell carcinoma.
  • To highlight the impact of novel therapeutics, including immune checkpoint inhibitors.
  • To discuss the ongoing investigations into optimal treatment sequencing and patient-centered outcomes.

Main Methods:

  • Review of recent clinical trials and therapeutic advancements in advanced RCC.
  • Analysis of the role of immune checkpoint inhibitors in refractory RCC.
  • Discussion of challenges and future directions in RCC treatment management.

Main Results:

  • Immune checkpoint inhibitors demonstrate significant promise in patients with advanced RCC, including those with treatment-refractory disease.
  • Optimal sequencing of therapies and integration of novel agents are still under active investigation.
  • Emerging treatments necessitate a focus on patient-centered outcomes, including quality of life, alongside survival benefits.

Conclusions:

  • The management of advanced renal cell carcinoma is undergoing a paradigm shift driven by immunotherapy and novel agents.
  • Further research is crucial to establish optimal treatment strategies, balancing efficacy, toxicity, and patient-centered outcomes.
  • Future directions emphasize personalized treatment approaches to improve both survival and quality of life for RCC patients.

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K